Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by lab testing of tissue) with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy.
• People who have been diagnosed (confirmed by lab testing of tissue) with a specific type of cancer called clear cell carcinoma, affecting the ovary, lining of the uterus (endometrium), vagina, vulva, or cervix.
• People whose cancer has come back or is still present, with evidence that it has grown or spread.
• People with platinum-resistant ovarian cancer who have received at least 1 but no more than 3 previous treatment courses for that cancer.
• People with clear cell cancer who have received at least 1 previous treatment course for that cancer.
• People with a known BRCA gene mutation (inherited or developed over time) where, if a PARP inhibitor drug was locally approved and available, that treatment was tried and either stopped working or was not tolerated.
• People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines.
• People who have stored tumour tissue available from a previous biopsy or surgery, or who are willing to have a new biopsy taken.
• People who are in acceptable general health and have blood and organ test results within acceptable ranges.
• People who are able to become pregnant must agree to use highly effective contraception throughout the trial.
• People who are not currently pregnant, not planning to become pregnant, and not breastfeeding.

Who may not be able to join:

• People with a medical or mental health condition that would make it difficult to safely receive or follow the planned treatment and study procedures.
• People whose cancer never responded to their very first platinum-based chemotherapy, or whose cancer progressed within 3 months of finishing that first course of treatment.
• People who have previously been treated with certain immune-based therapies called checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 drugs) — though this restriction may not apply to people with clear cell endometrial or clear cell cervical cancer (confirm with trial site).
• People who currently have active cancer spread to the brain or the lining around the brain and spinal cord.
• People who have previously had a stem cell, tissue, or solid organ transplant.
• People who have had fluid drained from their abdomen within 4 weeks before starting the trial treatment.
• People who have had another cancer (blood cancer or solid tumour, stage 1 or higher) where surgery, radiation, or anti-cancer treatment was completed within the last 3 years — though people with certain low-risk skin cancers or very early-stage cancers that have been well controlled may still be considered eligible (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.